欧州連合 - ノルウェー語 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - paclitaxel - breast neoplasms; pancreatic neoplasms; carcinoma, non-small-cell lung - antineoplastiske midler - abraxane monoterapi er indisert for behandling av metastatisk brystkreft hos voksne pasienter som har mislyktes behandling i første linje for metastatisk sykdom og for hvem standard antracyklinholdig terapi ikke er indikert. abraxane i kombinasjon med gemcitabine er angitt for det første-linje behandling av voksne pasienter med metastatisk adenocarcinoma i bukspyttkjertelen. abraxane i kombinasjon med carboplatin er angitt for det første-linje behandling av ikke-liten celle lunge kreft hos voksne pasienter som ikke er kandidater for potensielt kurativ kirurgi og/eller strålebehandling.

欧州連合 - ノルウェー語 - EMA (European Medicines Agency)

ucb pharma sa - brivaracetam - epilepsi - antiepileptics, - briviact er indisert som tilleggsbehandling ved behandling av delvis-utbruddet anfall med eller uten sekundær generalisering hos voksne og unge pasienter fra 16 år med epilepsi.

欧州連合 - ノルウェー語 - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloksetin - anxiety disorders; diabetic neuropathies; depressive disorder, major - psychoanaleptics, - behandling av alvorlig depressiv lidelse. behandling av diabetisk perifer neuropatisk smerte. behandling av generalisert angst lidelse. cymbalta er indisert hos voksne.

欧州連合 - ノルウェー語 - EMA (European Medicines Agency)

janssen-cilag international n.v.   - decitabine - leukemi, myeloid - antineoplastiske midler - behandling av voksne pasienter med nylig diagnostisert de novo eller sekundær akutt myeloide leukemi (aml), i henhold til who-klassifikasjonen, som ikke er kandidater for standard induksjonskreoterapi.

欧州連合 - ノルウェー語 - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloksetin - neuralgia; diabetic neuropathies; depressive disorder, major - psychoanaleptics, - duloxetine lilly er indisert hos voksne:behandling av depressive disordertreatment av diabetiker perifer nevropatisk paintreatment av generell angst disorderduloxetine lilly er indisert hos voksne.

欧州連合 - ノルウェー語 - EMA (European Medicines Agency)

mylan pharmaceuticals limited - duloksetin - neuralgia; diabetic neuropathies; depressive disorder, major; anxiety disorders - psychoanaleptics, - behandling av store depressiv lidelse, behandling av smerter ved perifer diabetisk nevropati;behandling av generalisert angst lidelse;duloxetine mylan er indisert hos voksne.

欧州連合 - ノルウェー語 - EMA (European Medicines Agency)

zentiva, k.s. - duloksetin - neuralgia; depressive disorder, major; anxiety disorders; diabetes mellitus - andre antidepressiva - behandlings depressiv lidelse, diabetisk nevropatisk smerte, angstlidelse. duloxetine zentiva er indisert hos voksne.

欧州連合 - ノルウェー語 - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

欧州連合 - ノルウェー語 - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozin - diabetes mellitus, type 2 - legemidler som brukes i diabetes - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5.

欧州連合 - ノルウェー語 - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil hydrochloride - colorektale neoplasmer - antineoplastiske midler - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.